It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATEC’s FA Score shows that 0 FA rating(s) are green whileEKSO’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATEC’s TA Score shows that 5 TA indicator(s) are bullish while EKSO’s TA Score has 6 bullish TA indicator(s).
ATEC (@Medical/Nursing Services) experienced а +0.63% price change this week, while EKSO (@Pharmaceuticals: Other) price change was +16.12% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.89%. For the same industry, the average monthly price growth was +5.50%, and the average quarterly price growth was +9.92%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.91%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was +15.22%.
ATEC is expected to report earnings on Oct 30, 2025.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+3.91% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
ATEC | EKSO | ATEC / EKSO | |
Capitalization | 2.37B | 10.2M | 23,255% |
EBITDA | -46.79M | -9.25M | 506% |
Gain YTD | 74.619 | -57.486 | -130% |
P/E Ratio | N/A | N/A | - |
Revenue | 682M | 14.7M | 4,639% |
Total Cash | 157M | 5.24M | 2,995% |
Total Debt | 587M | 5.39M | 10,889% |
ATEC | EKSO | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 44 Fair valued | |
PROFIT vs RISK RATING 1..100 | 52 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 92 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EKSO's Valuation (44) in the Medical Specialties industry is somewhat better than the same rating for ATEC (99). This means that EKSO’s stock grew somewhat faster than ATEC’s over the last 12 months.
ATEC's Profit vs Risk Rating (52) in the Medical Specialties industry is somewhat better than the same rating for EKSO (100). This means that ATEC’s stock grew somewhat faster than EKSO’s over the last 12 months.
ATEC's SMR Rating (100) in the Medical Specialties industry is in the same range as EKSO (100). This means that ATEC’s stock grew similarly to EKSO’s over the last 12 months.
ATEC's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for EKSO (92). This means that ATEC’s stock grew somewhat faster than EKSO’s over the last 12 months.
ATEC's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as EKSO (100). This means that ATEC’s stock grew similarly to EKSO’s over the last 12 months.
ATEC | EKSO | |
---|---|---|
RSI ODDS (%) | 1 day ago79% | 2 days ago86% |
Stochastic ODDS (%) | 1 day ago78% | 1 day ago89% |
Momentum ODDS (%) | 1 day ago74% | 1 day ago82% |
MACD ODDS (%) | 1 day ago65% | 1 day ago81% |
TrendWeek ODDS (%) | 1 day ago83% | 1 day ago79% |
TrendMonth ODDS (%) | 1 day ago82% | 1 day ago76% |
Advances ODDS (%) | 2 days ago85% | 1 day ago81% |
Declines ODDS (%) | 22 days ago82% | 14 days ago87% |
BollingerBands ODDS (%) | 1 day ago77% | 1 day ago84% |
Aroon ODDS (%) | 1 day ago82% | 1 day ago73% |
A.I.dvisor tells us that EKSO and MBOT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EKSO and MBOT's prices will move in lockstep.
Ticker / NAME | Correlation To EKSO | 1D Price Change % | ||
---|---|---|---|---|
EKSO | 100% | +2.37% | ||
MBOT - EKSO | 27% Poorly correlated | -1.72% | ||
ATEC - EKSO | 25% Poorly correlated | -0.93% | ||
RVP - EKSO | 24% Poorly correlated | +1.20% | ||
NMTC - EKSO | 24% Poorly correlated | -1.48% | ||
TMDX - EKSO | 24% Poorly correlated | -0.56% | ||
More |